Fidaxomicin Use and Clinical Outcomes for Clostridium difficile–Associated Diarrhea

BACKGROUND: Fidaxomicin has been scrutinized because of its high acquisition cost. Real-world experience is needed to determine whether fidaxomicin has value in patients with Clostridium difficile–associated diarrhea (CDAD) and certain risk factors. METHODS: In this single-center, retrospective coho...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Infect Dis Clin Pract (Baltim Md)
Asıl Yazarlar: Eiland, Edward H., Sawyer, Adam J., Massie, Nicholas L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Lippincott Williams & Wilkins 2015
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4280276/
https://ncbi.nlm.nih.gov/pubmed/25574116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IPC.0000000000000181
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller